Dranitsaris, George; Mehta, Sanjay - In: Applied Health Economics and Health Policy 7 (2009) 1, pp. 43-59
Ambrisentan is less costly than other available ERAs, including bosentan and sitaxentan, but is more costly than sildenafil. In PAH patients in whom an ERA is the preferred agent, ambrisentan may be the drug of choice because of its economic advantages and improved safety profile. </AbstractSection> Copyright...